Implications of peginterferon use in special populations infected with HCV

Seminars in Liver Disease

Volumn 23, Issue SUPPL. 1, 2003, Pages 47-52

  Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Alcohol; HCV; HIV; Quasispecies; Race; Treatment; Viral load

Indexed keywords

ALCOHOL; DIDANOSINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBETRON; RIBAVIRIN;

ALCOHOL ABUSE; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; ERADICATION THERAPY; FACTORIAL ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INDIVIDUALIZATION; LABORATORY DIAGNOSIS; NEGRO; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL KINETIC MODELING; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INFECTION;

AFRICAN AMERICANS; ALCOHOLISM; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 0041317662     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
3. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2a. Gastroenterology 2001;120:1438-1447
4. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837
5. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. Hepatology 1999;30:1054-1058
6. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497
7. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;36:363-367
8. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002;100:1584-1589
9. Sherman KE. Diagnosis and management of the HCV/HIV-coinfected patient. AIDS Clin Care 2002;14:39-43, 48
10. Sherman KE, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis 2002;35:482-487
11. Bonacini M, Govindarajan S, Blatt LM, et al. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999;6:203-208
12. Ragni MV, Bontempo FA. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active anti-retroviral therapy. J Infect Dis 1999;180:2027-2029
13. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002;16:1915-1923
14. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562
15. Landau A, Batisse D, Van Huyen PJ, et al. Efficacy and safety of combination therapy with interferon alpha-2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000;14:839-844
16. Zylberberg H, Benhamou Y, Ligneous JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000;47:694-697
17. Hino K, Yamaguchi Y, Fujiwara D, et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 2000;7:36-42
18. Pawlotsky JM, Pellerin M, Bouvier M, et al. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 1998;54:256-264
19. Sherman KE, Andreatta C, O'Brien J, et al. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 1996;23:688-694
20. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996;23:585-591
21. Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998;26:16-19
22. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15:2149-2155
23. Sauleda S, Juarez A, Esteban JI, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;34:1035-1040
24. Chung RAJ, Alston B, Vallee, M, et al. A randomized controlled trial of pegylated interferon-alfa-2a with ribavirin vs. interferon-alfa-2a with ribavirin for treatment of chronic HCV in HIV Co-infection. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002
25. Sherman KE, Horn P. Rouster S, et al. HCV RNA kinetic response to PEG-interferon and ribavirin in HCV co-infected patients. Presented at the 9th Conference on Retrovirus and Opportunistic Infections, Seattle, WA, February 2002
26. Perrone C, Carrat F, Sadr F, et al. RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin vs. interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. Presented at the XIV International Conference on AIDS, Barcelona, Spain, July 7-12, 2002
27. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-281
28. Boxwell D FR, Sheman KE. Evidence suggesting mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin and certain anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs). Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2003
29. Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology 1991;14:581-589
30. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809
31. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996;91:1374-1379
32. Sherman KE, Mendenhall C, Thee DL, et al. Hepatitis C serotypes in nonalcoholic and alcoholic patients. Dig Dis Sci 1997;42:2285-2291
33. Sherman KE, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity, in patients with alcoholic liver disease. Hepatology 1999;30:265-270
34. Takahashi K, Takahashi T, Takahashi S, et al. Difference in quasispecies of the hypervariable region 1 of hepatitis C virus between alcoholic and non-alcoholic patients. J Gastroenterol Hepatol 2001;16:416-423
35. Mendenhall CL, Finkelman F, Means RT Jr, et al. Cytokine response to BCG infection in alcohol-fed mice. Alcohol 1999;19:57-63
36. Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994;29:1039-1043
37. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30:787-793
38. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-1323
39. Keenan E RS, Sherman KE. Complexity and diversity of HCV RNA in African Americans. Hepatology 2002;36:207A
40. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001;65:510-516